KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Accounts Payables: 2020-2024

Historic Accounts Payables for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $21.6 million.

  • Recursion Pharmaceuticals' Accounts Payables rose 516.59% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 516.59%. This contributed to the annual value of $21.6 million for FY2024, which is 446.75% up from last year.
  • Recursion Pharmaceuticals' Accounts Payables amounted to $21.6 million in FY2024, which was up 446.75% from $4.0 million recorded in FY2023.
  • Recursion Pharmaceuticals' Accounts Payables' 5-year high stood at $21.6 million during FY2024, with a 5-year trough of $1.1 million in FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $4.6 million (2022), whereas its average is $10.1 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first fell by 13.80% in 2023, then spiked by 446.75% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Accounts Payables (Yearly) stood at $1.1 million in 2020, then soared by 162.48% to $2.8 million in 2021, then spiked by 62.68% to $4.6 million in 2022, then dropped by 13.80% to $4.0 million in 2023, then soared by 446.75% to $21.6 million in 2024.